Delving into the Latest Updates on KHN702 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

KHN702

Target

Nav1.8

Action

blockers

Mechanism

Nav1.8 blockers(Sodium channel protein type X alpha subunit blockers)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Pain, PostoperativeAcute Pain

Inactive Indication-

Originator Organization

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Active Organization

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objectives: ● To evaluate the safety and tolerability of single/multiple administration of KHN702 tablets in healthy subjects. Secondary objectives: ● To evaluate the pharmacokinetic characteristics of KHN702 after single/multiple oral administration in healthy subjects. ● To explore the effect of KHN702 tablets on QTc interval.

Start Date-

Sponsor / Collaborator

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with KHN702

Login to view more data

100 Translational Medicine associated with KHN702

Login to view more data

100 Patents (Medical) associated with KHN702

Login to view more data

100 Deals associated with KHN702

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain, Postoperative	Phase 1	China	Chengdu Kanghong Pharmaceutical Group Co., Ltd.	26 Nov 2025
Acute Pain	Phase 1	China	Chengdu Kanghong Pharmaceutical Group Co., Ltd.	17 Jun 2025